AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Grifols S.A. (GRFS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

7.45

0.13 (1.78%)

At close: Feb 18, 2025, 3:59 PM

7.34

-1.41%

After-hours: Feb 18, 2025, 06:54 PM EST

undefined% (undefined)

Bid	6.9
Market Cap	6.06B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.25
PE Ratio (ttm)	29.78
Forward PE	n/a
Analyst	Sell

Ask	7.8
Volume	359,874
Avg. Volume (20D)	952,677
Open	7.63
Previous Close	7.32
Day's Range	7.40 - 7.63
52-Week Range	5.30 - 9.96
Beta	undefined

About GRFS

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunogl...

[Show more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Jun 2, 2011

Employees 23,000

Stock Exchange NASDAQ

Ticker Symbol GRFS

Website https://www.grifols.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for GRFS stock is "Sell." The 12-month stock price forecast is $10.5, which is an increase of 41.03% from the latest price.

Buy 0.00%

Hold 50.00%

Sell 50.00%

Stock Forecasts

Why Price Moved

2 months ago

Grifols shares are trading lower after the company... Unlock content with Pro Subscription

3 months ago

+5.06%

Grifols shares are trading higher following a report suggesting banks are preparing to submit final offers for a buyout debt deal.

News

1 month ago · reuters.com

Mason Capital complains about Grifols' transparency to Spanish regulator

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols.

1 month ago · businesswire.com

Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. (“Grifols” or the “Company”) (BME: G...

2 months ago · businesswire.com

Flat Footed Calls for Prompt Governance Overhaul at Grifols

BARCELONA, Spain--(BUSINESS WIRE)--Flat Footed LLC is the investment manager for FF Hybrid LP, Flat Footed Series LLC - Fund 3, and GP Recovery Fund LLC (collectively, with Flat Footed LLC, “Flat Foot...

2 months ago · businesswire.com

Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: G...

2 months ago · businesswire.com

Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols

MADRID--(BUSINESS WIRE)--Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the “Clients”) holding in aggregate 5.65% of A shares and 3.88% of B s...

2 months ago · seekingalpha.com

Grifols: More Attractive Than In A Very Long Time

I don't divest unless the fundamental thesis changes; Grifols' buyout offer from Brookfield Asset Management is undervalued, so I maintain my "Buy" stance. Despite Brookfield's offer, I believe Grifol...

2 months ago · benzinga.com

Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.

2 months ago · zacks.com

Grifols Stock Declines After Brookfield Drops Buyout Offer

Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.

2 months ago · reuters.com

Grifols shares tumble after report on Brookfield abandoning takeover plan

Shares in Grifols were falling on Wednesday morning after Bloomberg reported Canadian fund Brookfield is considering dropping its plan to take over the Spanish pharmaceutical firm.

3 months ago · zacks.com

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Load More News